| Revision as of 15:56, 14 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wik← Previous edit |
Latest revision as of 06:01, 31 December 2023 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers48,628 edits →top: infobox |
| (36 intermediate revisions by 23 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
| ⚫ |
| verifiedrevid = 447572916 |
|
|
|
| Watchedfields = changed |
|
| IUPAC_name = |
|
|
⚫ |
| verifiedrevid = 450486588 |
|
| image = |
|
|
|
| IUPAC_name = (4S,6R)-6-oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate |
|
|
|
|
|
| image = File:Heparin General Structure V.1.svg |
|
<!--Clinical data--> |
|
<!-- Clinical data --> |
|
| tradename = |
|
|
|
| tradename = Fraxiparin(e), Fraxodi, others |
|
| Drugs.com = {{drugs.com|international|nadroparin-calcium}} |
|
| Drugs.com = {{drugs.com|international|nadroparin-calcium}} |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| legal_AU = S4 |
|
|
| legal_CA = Rx-only |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
|
| legal_UK = |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = ] (except for ]) |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
|
⚫ |
| bioavailability = 89% (SC dose) |
| ⚫ |
<!--Pharmacokinetic data--> |
|
| ⚫ |
| bioavailability = |
|
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = 3.7 hours (SC dose) |
|
| excretion = |
|
| excretion = clearance 21.4mL/min (+/- 7) |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ⚫ |
<!--Identifiers--> |
|
|
| CAS_number = |
|
| ChemSpiderID = none |
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
|
| CAS_number = 9005-49-6 |
|
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = 1K5KDI46KZ |
|
| ATC_prefix = B01 |
|
| ATC_prefix = B01 |
|
| ATC_suffix = AB06 |
|
| ATC_suffix = AB06 |
|
| PubChem = |
|
| PubChem = |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
|
| DrugBank = |
|
| DrugBank = DB08813 |
|
|
| KEGG_Ref = {{keggcite|changed|kegg}} |
|
|
| KEGG = D07510 |
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
⚫ |
| ChEMBL = <!-- Chemical data --> |
|
⚫ |
| chemical_formula = |
|
⚫ |
| molecular_weight = 4300 |
|
|
| molecular_weight_comment = g/mol |
|
⚫ |
}} |
|
|
'''Nadroparin''' (trade names '''Fraxiparin''', '''Fraxodi''', among others) is an anticoagulant belonging to a class of drugs called ]s (LMWHs). Nadroparin was developed by ]. |
|
|
|
|
|
|
Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (] and ]), and as treatment for ]. It is also used to prevent clotting during ], and for treatment of ] and non-Q wave ].<ref name= "Aspri Canada">{{cite web|title=Fraxiparine PRODUCT MONOGRAPH (Canada)|url=http://www.aspripharma.com/pdf/Fraxiparine%20&%20Fraxi%20Forte%20PM_EN.pdf|website=Aspripharma.com|access-date=2 April 2019}}</ref> |
| ⚫ |
<!--Chemical data--> |
|
| ⚫ |
| chemical_formula = |
|
|
|
|
|
|
|
For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the abdomen. It is on the ].<ref name="WHO22nd">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref> |
| ⚫ |
| molecular_weight = Mean MW = 4500 Daltons |
|
|
|
|
| ⚫ |
}} |
|
|
⚫ |
==References== |
|
'''Nadroparin''' is a form of ] sold by ] under trademark '''Fraxiparine'''<ref>GSK PRODUCT MONOGRAPH; http://www.gsk.ca/english/docs-pdf/Fraxiparine_2011.pdf</ref>. |
|
|
|
{{Reflist}} |
| ⚫ |
== References == |
|
|
{{reflist}} |
|
|
|
|
|
|
==External links== |
|
==External links== |
|
|
* {{cite web|url=https://www.cancer.gov/publications/dictionaries/cancer-drug|title=NCI Drug Dictionary|date=2 February 2011|website=National Cancer Institute|access-date=2 April 2019}} |
|
* http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128 |
|
|
⚫ |
* {{cite journal |vauthors=Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A |title=A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study |journal=Pharmacology |volume=78 |issue=3 |pages=136–43 |year=2006 |pmid=17057417 |doi=10.1159/000096484|s2cid=95878036 }} |
|
* http://www.mayoclinic.com/health/drug-information/DR600971 |
|
| ⚫ |
* {{cite journal |author=Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A |title=A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study |journal=Pharmacology |volume=78 |issue=3 |pages=136–43 |year=2006 |pmid=17057417 |doi=10.1159/000096484}} |
|
|
|
|
|
|
{{Antithrombotics}} |
|
{{Antithrombotics}} |
|
|
|
|
|
⚫ |
] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
{{blood-drug-stub}} |
|
{{blood-drug-stub}} |
|
|
|
|
] |
|
|
] |
|
|
] |
|
| ⚫ |
] |
|